Medicine and Dentistry
Gallium 68
100%
Positron Emission Tomography
76%
Fluorine-18
71%
Neoplasm
67%
Polyethylene Terephthalate
67%
Radioactive Tracer
62%
Positron Emission Tomography-Computed Tomography
62%
Prostate Cancer
61%
Prostate Specific Membrane Antigen
50%
Chemokine Receptor
38%
Molecular Imaging
22%
Carbon 11
22%
Integrin
21%
Biodistribution
18%
Lutetium 177
18%
Fluorodeoxyglucose F 18
17%
Dosimetry
16%
Standardized Uptake Value
13%
Diseases
12%
Radiation Therapy
12%
Malignant Neoplasm
12%
Biochemical Recurrence
12%
Prostate Specific Antigen
11%
Magnetic Resonance Imaging
11%
Choline
11%
In Vitro
11%
Octreotide
11%
Metastatic Carcinoma
11%
Chemokine Receptor CXCR4
11%
Radioligand
10%
Positron Emission Tomography - Magnetic Resonance Imaging
10%
Radiopharmaceutical
9%
Tetraxetan
9%
Alzheimer's Disease
9%
Immunohistochemistry
9%
Multiple Myeloma
9%
Gamma Chemokine
8%
Indium 111
8%
Prostatectomy
8%
Receptor
8%
Pharmacokinetics
8%
Radiosurgery
8%
Somatostatin Receptor
8%
Lymph Node
7%
Autoradiograph
7%
Iodine 125
7%
Amyloid Protein
7%
Biological Marker
6%
Ex Vivo
6%
Tumor Xenograft
6%
Keyphrases
Prostate-specific Antigen
68%
Positron Emission Tomography
67%
C-X-C Chemokine Receptor Type 4 (CXCR4)
65%
Positron Emission Tomography-computed Tomography (PET-CT)
58%
Gallium-68
58%
Tumor
47%
68Ga-pentixafor
36%
Prostate Cancer
35%
Integrin
31%
Lutetium-177 (177Lu)
31%
18F-labeled
27%
Biodistribution
24%
PET Imaging
22%
Molecular Imaging
22%
Standardized Uptake Value
19%
Chelator
18%
Radiopharmaceuticals
18%
CXCR4 Expression
18%
Preclinical Evaluation
16%
Octreotide
15%
Hybrid Radio
14%
Pharmacokinetics
14%
Kidney
14%
Tumor Uptake
13%
18F-fluorodeoxyglucose (18F-FDG)
13%
Integrin Expression
13%
Endoradiotherapy
13%
Pentixafor
13%
125I
12%
PET-MRI
12%
High Affinity
12%
Alzheimer's Disease
12%
SUVmax
11%
Theranostics
11%
Chemokine Receptor CXCR4
11%
Liver
11%
Amyloid Plaques
11%
Radiotracer
10%
Tracer Uptake
10%
Radiochemical Yield
10%
Radioligand Therapy
10%
After Injection
9%
Chemokine Receptor
9%
Immunohistochemistry
9%
PET Tracer
9%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
9%
Angiogenesis
9%
18F-fluorothymidine
9%
IC50
9%
Technetium-99m
9%
Pharmacology, Toxicology and Pharmaceutical Science
Fluorine 18
68%
Polyethylene Terephthalate
64%
Neoplasm
62%
Gallium 68
51%
Tracer
45%
Prostate Specific Membrane Antigen
34%
Prostate Cancer
28%
Lutetium 177
25%
Integrin
24%
Receptor
20%
Biodistribution
19%
Pharmacokinetics
18%
Tetraxetan
16%
Radioligand
15%
Carbon 11
14%
Malignant Neoplasm
13%
Dosimetry
11%
Iodine-125
11%
Chelating Agent
10%
Radioisotope
10%
Chemokine Receptor
9%
Octreotide
9%
Castration Resistant Prostate Cancer
9%
Technetium 99m
8%
IC50
8%
Diseases
8%
Amino Acid
7%
Amyloid Protein
7%
Prostate Specific Antigen
6%
Somatostatin Receptor
6%
Biochemical Recurrence
6%
Lipophilicity
6%
Opiate Receptor
6%